Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 125,000 shares of the stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $53.22, for a total value of $6,652,500.00. Following the completion of the transaction, the insider now directly owns 125,341 shares in the company, valued at approximately $6,670,648.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Biohaven Pharmaceutical stock traded up $2.18 during midday trading on Tuesday, reaching $55.92. The stock had a trading volume of 645,368 shares, compared to its average volume of 667,844. The company has a fifty day moving average of $54.42 and a 200 day moving average of $46.07. The firm has a market cap of $2.81 billion, a price-to-earnings ratio of -9.09 and a beta of 0.43. Biohaven Pharmaceutical Holding Co Ltd has a 52-week low of $34.06 and a 52-week high of $67.86.
Biohaven Pharmaceutical (NYSE:BHVN) last announced its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.47). On average, equities analysts forecast that Biohaven Pharmaceutical Holding Co Ltd will post -7.61 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently bought and sold shares of BHVN. Nuveen Asset Management LLC acquired a new stake in Biohaven Pharmaceutical in the 2nd quarter worth approximately $38,799,000. Eventide Asset Management LLC lifted its holdings in shares of Biohaven Pharmaceutical by 98.5% during the third quarter. Eventide Asset Management LLC now owns 1,634,000 shares of the company’s stock worth $68,170,000 after buying an additional 811,000 shares during the last quarter. State Street Corp lifted its holdings in shares of Biohaven Pharmaceutical by 28.8% during the third quarter. State Street Corp now owns 2,044,943 shares of the company’s stock worth $85,315,000 after buying an additional 456,986 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Biohaven Pharmaceutical by 236.8% during the second quarter. Bank of New York Mellon Corp now owns 545,594 shares of the company’s stock worth $23,892,000 after buying an additional 383,594 shares during the last quarter. Finally, Brown Advisory Inc. lifted its holdings in shares of Biohaven Pharmaceutical by 60.7% during the second quarter. Brown Advisory Inc. now owns 1,008,046 shares of the company’s stock worth $44,144,000 after buying an additional 380,764 shares during the last quarter. Hedge funds and other institutional investors own 92.83% of the company’s stock.
Several research firms have weighed in on BHVN. Piper Jaffray Companies reissued a “buy” rating and issued a $100.00 target price on shares of Biohaven Pharmaceutical in a research note on Monday, December 23rd. William Blair reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, December 10th. Wedbush began coverage on Biohaven Pharmaceutical in a research note on Thursday, December 12th. They issued an “outperform” rating and a $75.00 target price on the stock. Leerink Swann increased their target price on Biohaven Pharmaceutical from $62.00 to $64.00 and gave the company an “outperform” rating in a research note on Friday, December 6th. Finally, Cantor Fitzgerald raised their price target on Biohaven Pharmaceutical from $87.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, October 28th. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $71.42.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.
